Certara acquires Chemaxon

Certara acquired Chemaxon for $96.4 million, a transaction completed in October 2024, structured as all cash.

Chemaxon operates in Software, is based in Hungary (Chemaxon Kft.), had revenue of about Expected software revenue greater than $20 million in 2024.. Chemaxon (Chemaxon Kft.) is a cheminformatics software company whose products handle chemical structure drawing, property prediction, search and analysis, helping research scientists digitize the design-make-test-analyze (DMTA) lifecycle to identify new chemical leads. Certara - which had partnered with Chemaxon for about ten years - acquired 100% of the equity for total cash consideration of $96.4 million ($87.4 million to sellers plus $9.0 million to escrow), funded in part by new term debt. The deal positioned Certara in the drug-discovery biosimulation market at scale, complementing its later-phase development portfolio. Chemaxon was expected to generate more than $20 million of software revenue in 2024.

Position Certara in drug-discovery biosimulation at scale and offer a comprehensive data and predictive-analytics platform from discovery through commercialization.

Longtime ~10-year partner; growth profile comparable to Certara's software business, expected to reach an adjusted EBITDA margin near Certara's corporate average by end of 2025. Combined predictive analytics platform spanning discovery through commercialization.

Advisory firms were not disclosed for this transaction.